Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

51 52 Next >

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender ↗

June 17, 2024

The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.

Via Investor's Business Daily

Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects ↗

June 17, 2024

Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.

Via Benzinga

Topics Death

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar ↗

June 14, 2024

The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.

Via Investor's Business Daily

What 8 Analyst Ratings Have To Say About Gilead Sciences ↗

June 14, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 13, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗

June 05, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗

May 21, 2024

Via Benzinga

Market Whales and Their Recent Bets on GILD Options ↗

May 15, 2024

Via Benzinga

Decoding Gilead Sciences's Options Activity: What's the Big Picture? ↗

May 10, 2024

Via Benzinga

3 Stocks With Mouthwatering Dividends You Can Buy Right Now ↗

June 08, 2024

These stocks offer great dividends and more.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 07, 2024

Via Benzinga

Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100? ↗

June 05, 2024

If you're looking for big income from blue-chip companies, these picks are for you.

Via The Motley Fool

The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream ↗

June 05, 2024

Looking for some safe higher-yielding dividend stocks today? These are seven of the best options in this volatile market.

Via InvestorPlace

7 Dividend Stocks to Invest In for a Lifetime of Income ↗

June 05, 2024

Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment.

Via InvestorPlace

Why NASDAQ:GILD qualifies as a good dividend investing stock. ↗

May 09, 2024

Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors.

Via Chartmill

$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today ↗

May 07, 2024

Via Benzinga

Gilead Sciences Unusual Options Activity For May 06 ↗

May 06, 2024

Via Benzinga

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection ↗

June 04, 2024

The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate...

Via Benzinga

3 Dividend Stocks That Even Ken Griffin Is Buying ↗

June 04, 2024

Billionaire investor Ken Griffin is filling the portfolio of his Citadel Advisors hedge fund with dividend paying stocks.

Via InvestorPlace

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies ↗

June 03, 2024

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response...

Via Benzinga

Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer ↗

May 31, 2024

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed...

Via Benzinga

Is Nvidia Worth 35x Times Sales, History Says No ↗

May 29, 2024

You wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but Tuesday was a pretty negative day, with the S&P 500 equal weight RSP ETF finishing down by almost 70 bps.

Via Talk Markets

Topics ETFs Stocks

2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years ↗

May 28, 2024

These companies have grown their dividends despite some troubles.

Via The Motley Fool

7 Biotech Stocks to Put on Your Breakthrough Radar ↗

May 27, 2024

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Via InvestorPlace

3 Biotech Stocks to Buy Now: May 2024 ↗

May 22, 2024

As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.

Via InvestorPlace

Large Cap Biopharmaceuticals Performance ↗

May 20, 2024

The biotech sector remains a laggard YTD as can be seen by the IBB.

Via Talk Markets

Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch ↗

May 20, 2024

Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.

Via Benzinga

Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch ↗

May 16, 2024

Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns.

Via InvestorPlace

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗

May 09, 2024

These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.

Via InvestorPlace

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Starting at $3.75/week.

Subscribe Today